SMOFlipid® (lipid injectable emulsion)

Phase 3

FFresenius

SMOFlipid® (lipid injectable emulsion) is one of 3 therapeutic programs targeting Child. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ChildRecruiting

ChildPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Child

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 2

1 2

SMOFlipid® (lipid injectable emulsion)

FFresenius

Phase 3

1 3

Hydroxychloroquin

RRadboud University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

ApprovedRecruiting

Child

NCT06049680

Clinical

Trials by Indication[1]

Child1 trial

A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and/or Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Years of Age and in Adult Patients, Who Are Anticipated to Need 8 Weeks or Longer of Parenteral Nutrition Treatment

Recruiting·FFresenius·Approved·NCT06049680·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SMOFlipid® (lipid injectable emulsion). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SMOFlipid® (lipid injectable emulsion). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fresenius company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: FFresenius

SMOFlipid® (lipid injectable emulsion)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Child1 trial

References

Drug Info

Quick Facts

Related News